When siRNA-BACE1, a therapeutic target for Alzheimer’s disease, was loaded into these sEVs, the modified sEVs significantly reduced the mRNA and protein levels of BACE1 in mouse nerve cells. Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.